Recent Finacing
Recent Raise
Augustine Therapeutics develops subtype-selective, non-hydroxamate small-molecule HDAC6 inhibitors, including the peripherally restricted AGT-100216, for chronic neuromuscular, neurodegenerative, and cardiometabolic indications; spun out from VIB–KU Leuven.
